Harrow, Inc. (NASDAQ:HROW) Shares Purchased by Swiss National Bank

Swiss National Bank raised its holdings in Harrow, Inc. (NASDAQ:HROW) by 1.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,300 shares of the company’s stock after purchasing an additional 600 shares during the period. Swiss National Bank’s holdings in Harrow were worth $1,990,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Quest Partners LLC bought a new stake in shares of Harrow during the 3rd quarter worth about $29,000. China Universal Asset Management Co. Ltd. raised its stake in Harrow by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after purchasing an additional 727 shares during the period. HighTower Advisors LLC boosted its position in Harrow by 13.8% during the 4th quarter. HighTower Advisors LLC now owns 10,127 shares of the company’s stock worth $340,000 after acquiring an additional 1,227 shares during the period. Avantax Advisory Services Inc. grew its position in Harrow by 11.3% during the fourth quarter. Avantax Advisory Services Inc. now owns 12,534 shares of the company’s stock valued at $421,000 after purchasing an additional 1,273 shares in the last quarter. Finally, AlphaQuest LLC increased its stake in shares of Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after acquiring an additional 2,889 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Price Performance

Harrow stock opened at $26.21 on Friday. The business’s fifty day moving average is $28.90 and its two-hundred day moving average is $38.01. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a market cap of $933.47 million, a P/E ratio of -27.88 and a beta of 0.69. Harrow, Inc. has a 52 week low of $9.86 and a 52 week high of $59.23.

Harrow (NASDAQ:HROW) last released its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. The company had revenue of $66.83 million for the quarter, compared to the consensus estimate of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. Equities research analysts forecast that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on HROW shares. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Harrow in a research report on Tuesday, March 18th. B. Riley cut their price target on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.